Companies › Prospect Therapeutics (Nanjing)
2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PSTB100 | – | Phase 1 | Healthy Adult Subjects | Jun 2027 |
| PSTC100 tablets | – | Phase 1 | Healthy Adult Subjects | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07702279 | PSTB100 | Phase 1 | Healthy Adult Subjects | Other | Jun 2027 |
| NCT07752472 | PSTC100 tablets | Phase 1 | Healthy Adult Subjects | Other | Jul 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.